Novel drug combination nanoparticles exhibit enhanced plasma exposure and dose-responsive effects on eliminating breast cancer lung metastasis.
Early diagnosis along with new drugs targeted to cancer receptors and immunocheckpoints have improved breast cancer survival. However, full remission remains elusive for metastatic breast cancer due to dose-limiting toxicities of heavily used, highly potent drug combinations such as gemcitabine and...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2020-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0228557 |
| _version_ | 1811166084403822592 |
|---|---|
| author | Qingxin Mu Jesse Yu James I Griffin Yan Wu Linxi Zhu Lisa A McConnachie Rodney J Y Ho |
| author_facet | Qingxin Mu Jesse Yu James I Griffin Yan Wu Linxi Zhu Lisa A McConnachie Rodney J Y Ho |
| author_sort | Qingxin Mu |
| collection | DOAJ |
| description | Early diagnosis along with new drugs targeted to cancer receptors and immunocheckpoints have improved breast cancer survival. However, full remission remains elusive for metastatic breast cancer due to dose-limiting toxicities of heavily used, highly potent drug combinations such as gemcitabine and paclitaxel. Therefore, novel strategies that lower the effective dose and improve safety margins could enhance the effect of these drug combinations. To this end, we developed and evaluated a novel drug combination of gemcitabine and paclitaxel (GT). Leveraging a simple and scalable drug-combination nanoparticle platform (DcNP), we successfully prepared an injectable GT combination in DcNP (GT DcNP). Compared to a Cremophor EL/ethanol assisted drug suspension in buffer (CrEL), GT DcNP exhibits about 56-fold and 8.6-fold increases in plasma drug exposure (area under the curve, AUC) and apparent half-life of gemcitabine respectively, and a 2.9-fold increase of AUC for paclitaxel. Using 4T1 as a syngeneic model for breast cancer metastasis, we found that a single GT (20/2 mg/kg) dose in DcNP nearly eliminated colonization in the lungs. This effect was not achievable by a CrEL drug combination at a 5-fold higher dose (i.e., 100/10 mg/kg GT). A dose-response study indicates that GT DcNP provided a therapeutic index of ~15.8. Collectively, these data suggest that GT DcNP could be effective against advancing metastatic breast cancer with a margin of safety. As the DcNP formulation is intentionally designed to be simple, scalable, and long-acting, it may be suitable for clinical development to find effective treatment against metastatic breast cancer. |
| first_indexed | 2024-04-10T15:47:49Z |
| format | Article |
| id | doaj.art-cb89d7d76ccd4535a410f364e5bbf9bc |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-10T15:47:49Z |
| publishDate | 2020-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-cb89d7d76ccd4535a410f364e5bbf9bc2023-02-12T05:31:19ZengPublic Library of Science (PLoS)PLoS ONE1932-62032020-01-01153e022855710.1371/journal.pone.0228557Novel drug combination nanoparticles exhibit enhanced plasma exposure and dose-responsive effects on eliminating breast cancer lung metastasis.Qingxin MuJesse YuJames I GriffinYan WuLinxi ZhuLisa A McConnachieRodney J Y HoEarly diagnosis along with new drugs targeted to cancer receptors and immunocheckpoints have improved breast cancer survival. However, full remission remains elusive for metastatic breast cancer due to dose-limiting toxicities of heavily used, highly potent drug combinations such as gemcitabine and paclitaxel. Therefore, novel strategies that lower the effective dose and improve safety margins could enhance the effect of these drug combinations. To this end, we developed and evaluated a novel drug combination of gemcitabine and paclitaxel (GT). Leveraging a simple and scalable drug-combination nanoparticle platform (DcNP), we successfully prepared an injectable GT combination in DcNP (GT DcNP). Compared to a Cremophor EL/ethanol assisted drug suspension in buffer (CrEL), GT DcNP exhibits about 56-fold and 8.6-fold increases in plasma drug exposure (area under the curve, AUC) and apparent half-life of gemcitabine respectively, and a 2.9-fold increase of AUC for paclitaxel. Using 4T1 as a syngeneic model for breast cancer metastasis, we found that a single GT (20/2 mg/kg) dose in DcNP nearly eliminated colonization in the lungs. This effect was not achievable by a CrEL drug combination at a 5-fold higher dose (i.e., 100/10 mg/kg GT). A dose-response study indicates that GT DcNP provided a therapeutic index of ~15.8. Collectively, these data suggest that GT DcNP could be effective against advancing metastatic breast cancer with a margin of safety. As the DcNP formulation is intentionally designed to be simple, scalable, and long-acting, it may be suitable for clinical development to find effective treatment against metastatic breast cancer.https://doi.org/10.1371/journal.pone.0228557 |
| spellingShingle | Qingxin Mu Jesse Yu James I Griffin Yan Wu Linxi Zhu Lisa A McConnachie Rodney J Y Ho Novel drug combination nanoparticles exhibit enhanced plasma exposure and dose-responsive effects on eliminating breast cancer lung metastasis. PLoS ONE |
| title | Novel drug combination nanoparticles exhibit enhanced plasma exposure and dose-responsive effects on eliminating breast cancer lung metastasis. |
| title_full | Novel drug combination nanoparticles exhibit enhanced plasma exposure and dose-responsive effects on eliminating breast cancer lung metastasis. |
| title_fullStr | Novel drug combination nanoparticles exhibit enhanced plasma exposure and dose-responsive effects on eliminating breast cancer lung metastasis. |
| title_full_unstemmed | Novel drug combination nanoparticles exhibit enhanced plasma exposure and dose-responsive effects on eliminating breast cancer lung metastasis. |
| title_short | Novel drug combination nanoparticles exhibit enhanced plasma exposure and dose-responsive effects on eliminating breast cancer lung metastasis. |
| title_sort | novel drug combination nanoparticles exhibit enhanced plasma exposure and dose responsive effects on eliminating breast cancer lung metastasis |
| url | https://doi.org/10.1371/journal.pone.0228557 |
| work_keys_str_mv | AT qingxinmu noveldrugcombinationnanoparticlesexhibitenhancedplasmaexposureanddoseresponsiveeffectsoneliminatingbreastcancerlungmetastasis AT jesseyu noveldrugcombinationnanoparticlesexhibitenhancedplasmaexposureanddoseresponsiveeffectsoneliminatingbreastcancerlungmetastasis AT jamesigriffin noveldrugcombinationnanoparticlesexhibitenhancedplasmaexposureanddoseresponsiveeffectsoneliminatingbreastcancerlungmetastasis AT yanwu noveldrugcombinationnanoparticlesexhibitenhancedplasmaexposureanddoseresponsiveeffectsoneliminatingbreastcancerlungmetastasis AT linxizhu noveldrugcombinationnanoparticlesexhibitenhancedplasmaexposureanddoseresponsiveeffectsoneliminatingbreastcancerlungmetastasis AT lisaamcconnachie noveldrugcombinationnanoparticlesexhibitenhancedplasmaexposureanddoseresponsiveeffectsoneliminatingbreastcancerlungmetastasis AT rodneyjyho noveldrugcombinationnanoparticlesexhibitenhancedplasmaexposureanddoseresponsiveeffectsoneliminatingbreastcancerlungmetastasis |